贺普丁联合抗乙肝特异性转移因子治疗慢性乙肝临床研究  

The Preliminary Study of Combination Therapy with Lamivudine and Spectcific Transfer Factor for Hepatilis B Virus

作　　者：周佳彦[1] 庄奕煌[2] 

机构地区：[1]福建医科大学附属第二医院,362000 [2]泉州市第一医院,362000

出　　处：《福建医药杂志》2001年第2期13-15,共3页Fujian Medical Journal

摘　　要：目的　探讨贺普丁联合抗乙肝特异性转移因子治疗慢性乙型肝炎的临床疗效及安全性。方法　对照组常规保肝治疗的基础上 ,贺普丁 10 0 mg,每日 1次 ,连用 1年。治疗组在对照组的基础上加用抗乙肝特异性转移因子注射剂 2 mg,肌注 ,每日 1次 ,连用 3个月 ,停 3个月后继续用 3个月。治疗后 3、6、12个月时查血清肝功能、HBe Ag、HBVDNA和 CD4+ / CD8+ 。结果　对照组 /治疗组 HBe Ag阴转率 10 .5 2 %～ 42 .11% / 2 7.18%～ 6 6 .6 7% ;HBVDNA阴转率84.2 1%～ 73.6 8% / 86 .11%～ 94.44 % ;AL T复常率 6 5 .79%～ 71.0 5 % / 77.78%～ 88.89% ;CD4+ / CD8+ 1.17± 0 .10 /1.45± 0 .2 9。各项指标随时间推移明显改善。结论　贺普丁对 HBV有明显的抑制作用 ,联合抗乙肝特异性转移因子治疗 ,特异性提高机体免疫功能 ,能明显提高疗效、费用适宜 。Objective:To study whether combination therapy with Lamivudine(LAM) and spectiffic transfer factor for hepatitis B virus(STF HB) was the effect and safety for treatment of chronic hepatitis B.Methods:The chronic hepatitis treated with either LAM(n=38 100mg.daily for 52 weeks) or LAM plus STF HB(n=36 100mg LAM daily plus 2mg STF HB daily for 12 weeks,stopping 12 weeks,continue using 12 weeks).The end of treatment response were evaluated based on the serum liverfunctional or thymphocyte and seronegative of HBeAg or PCRHBVDNA.Results:In combined treatment group and alone LAM group,there is a significantly statistical difference between the combined treatment group and the alone LAM group.36～52 weeks later ALT normalization rate for two groups were 77 18%～88 89% and 65 79%～71 05%.52 weeks later CD 4 +/CD 8 + two groups were 1 45±0 29 and 1 17±0 10 The serocoversion rate for HBeAg and HBVDNA were 27 78%～66 67%/10 52%～42 11% and 86 11%～94 44%/84 21%～89 47%.in 12～52 weeks.Conclusion:Combination therapy of LAM and STF HB has higher efficacy than LAM alone the treatment of the patients with chronic hepatitis B.

关 键 词：贺普丁 抗乙肝特异性转移 慢性乙型肝炎 联合治疗 

分 类 号：R512.62[医药卫生—内科学]